Cadila Healthcare has received USFDA approval for Haloperidol Decanoate injection used in treatment of schizophrenia. It is also used in the treatment of schizophrenia and […]
Zydus Cadila has received final USFDA approval to market generic Ranolazine Extended-Release tablets used for treatment of chronic angina in US markets. The company will […]
Cadila Pharma has received the Good Laboratory Practices Certification (GLP) from National Good Laboratory Practice compliance Monitoring Authority (NGCMA), Department of Science and Technology, Government […]
Zydus Cadila has received final USFDA to market Chlorthalidone tablets, used to treat high blood pressure. The drug will be marketed in the strengths of […]
Zydus Cadila has received final USFDA approval to market Ambrisentan tablets in in strengths of 5 mg and 10 mg in the American market. The […]
Cadila has received USFDA approval for Potassium Chloride extended-release capsules to market the same in United States. The product is used to treat or prevent […]
Zydus Cadila has received the final USFDA approval to market Acetazolamide ER Capsules. Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used […]
Cadila has received final USFDA approval to market antipsychotic drug Aripiprazole tablets in US markets. The drug will be marketed in the strengths of 2 […]
Zydus Cadila has received final USFDA approval to market Doxycycline Hyclate delayed-release tablets which are used to treat bacterial infections. The drug will be marketed […]
Zydus Cadila has received final USFDA approval to market generic Lansoprazole delayed release orally disintegrating tablets in the strengths of 15 mg and 30 mg. […]
Copyright © 2023 | WordPress Theme by MH Themes